Pharvaris (NASDAQ:PHVS) Sets New 12-Month Low – Time to Sell?

Shares of Pharvaris (NASDAQ:PHVS) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $14.00 and last traded at $14.85, with a volume of 294 shares trading hands. The stock had previously closed at $14.95.

Analysts Set New Price Targets

Separately, JMP Securities lifted their price objective on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Stock Down 0.5 %

The stock’s fifty day simple moving average is $16.49 and its 200 day simple moving average is $18.80. The firm has a market capitalization of $778.08 million, a PE ratio of -5.31 and a beta of -3.02.

Institutional Trading of Pharvaris

Several hedge funds have recently bought and sold shares of the stock. FMR LLC increased its stake in Pharvaris by 3.6% in the 4th quarter. FMR LLC now owns 5,395,370 shares of the company’s stock worth $103,429,000 after buying an additional 189,714 shares in the last quarter. Soleus Capital Management L.P. lifted its holdings in shares of Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock valued at $15,617,000 after acquiring an additional 216,483 shares during the last quarter. Octagon Capital Advisors LP boosted its holdings in shares of Pharvaris by 25.4% in the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock worth $14,914,000 after purchasing an additional 157,530 shares during the period. Rock Springs Capital Management LP increased its position in shares of Pharvaris by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company’s stock valued at $14,859,000 after purchasing an additional 18,200 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Pharvaris by 36.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after purchasing an additional 118,408 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.